pharmaceuticals

upgrade

Canaccord Genuity Doubles Price Target for Medivation

Medivation Inc. (NASDAQ: MDVN) received an upgrade from Canaccord Genuity on the heels of it continually increasing its 52-week high over the past month. This upgrade comes on analyst John ...
Read Full Story »
biotech

Analyst Sees Incyte Worth 70% More

Incyte Corp. (NASDAQ: INCY) has serious upside potential, but the inherent risk within it may be too much for some investors to bear. This stock is not for the risk ...
Read Full Story »
Biotechnology word cloud

Why Endo Wants to Acquire Auxilium So Much

Endo International PLC (NASDAQ: ENDP) made an unsolicited buyout offer to Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL). This news comes right after Auxilium announced that it entered into an agreement to ...
Read Full Story »
95992888

Is Avanir Pharma Fully Valued After Monday’s Rally?

Avanir Pharmaceuticals Inc. (NASDAQ: AVNR) posted amazing gains on Monday following the announcement of a successful Phase 1 trial for AVP-923. On the day, Avanir's stock price rose by 85% to ...
Read Full Story »
health care

U.S. Hepatitis Problem to Continue Driving These 4 Top Stocks

For a variety of reasons, the cases of chronic hepatitis in the United States have surged dramatically over the past 20 years. Currently, it is estimated that more than 3.2 ...
Read Full Story »
Biotechnology word cloud

Short Sellers Remain Vigilant Against Biotechs

The short interest report is out for the August 29 settlement date, and 24/7 Wall St. is focusing on the biotech sector. Short sellers are often active in biotech stocks, ...
Read Full Story »
145922793

Does New Data Make or Break NPS Pharmaceuticals?

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is up huge in regular trading on Wednesday, due to positive preliminary results of a clinical trial. The FDA has posted the briefing materials prior to ...
Read Full Story »
DNA

IPO Filing: Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc. has filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO). No terms were given for the offering, but it is valued ...
Read Full Story »
DNA

What This Skin Cancer Drug Approval Really Means to Merck

Merck & Co. Inc. (NYSE: MRK) has received approval from the FDA to bring its new drug to market. The drug is called Keytruda and it is designed to treat ...
Read Full Story »
180519466

Is Infinity Fully Valued Now, or Is More Upside Left?

Infinity Pharmaceuticals Inc. (NASDAQ: INFI) has seen its stock rise so much on a pact that you might just think it is a buyout. It turns out that the pact ...
Read Full Story »
biotech

Credit Suisse Positive on Some Biotechs, Very Cautious on Others

Credit Suisse has launched new biotech coverage on Wednesday with two analysts at the firm. The biotech sector has been a wealth-creation engine in recent years. What is interesting here ...
Read Full Story »
Pills

Credit Suisse’s 4 Top Pharmaceutical Stocks to Buy for the Rest of 2014

While technology has dominated as the leading sector in the S&P 500 this year, currently up more than 20%, investors may be surprised to learn that pharmaceuticals have shown solid ...
Read Full Story »
uncertainty market evolution

ETF Rebalance Could Make 5 Biotech Stocks Shoot Higher

When indices like the S&P 500 or the Russell 2000 rebalance at the end of quarters, there is often high volatility in stocks that need to be bought or sold, ...
Read Full Story »
biotech

Civitas Therpeutics Files for IPO

Civitas Therapeutics Inc. filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO). No terms were given in the filing, but the total is up ...
Read Full Story »
biotech

Rising Short Interest in Biotech Stocks

The short interest data is out for the August 15 settlement date. Short sellers might be inclined to bet against biotech companies because of their volatile behavior on the charts, ...
Read Full Story »